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Abstract
Background: Intracranial hemorrhage (ICH) is a recognized complication of adults treated with extracorporeal
membrane oxygenation (ECMO) and is associated with increased morbidity and mortality. However, the predictors
of ICH in this patient category are poorly understood. The purpose of this study was to identify predictors of ICH in
ECMO-treated adult patients.
Methods: We conducted a retrospective review of adult patients (≥18 years) treated with ECMO at the Karolinska
University Hospital (Stockholm, Sweden) between September 2005 and June 2016, excluding patients with ICH
upon admission or those who were treated with ECMO for less than 12 h. In a comparative analysis, the primary
end-points were the difference in baseline characteristics and predictors of hemorrhage occurrence (ICH vs. non-
ICH cohorts). The secondary end-point was difference in mortality between groups. Paired testing and uni- and
multivariate regression models were applied.
Results: Two hundred and fifty-three patients were included, of which 54 (21%) experienced an ICH during ECMO
treatment. The mortality for patients with ICH was 81% at 1 month and 85% at 6 months, respectively, compared to 28
and 33% in patients who did not develop ICH. When comparing ICH vs. non-ICH cohorts, pre-admission antithrombotic
therapy (p = 0.018), high pre-cannulation Sepsis-related Organ Failure Assessment (SOFA) coagulation score (p = 0.015),
low platelet count (p < 0.001), and spontaneous extracranial hemorrhage (p = 0.045) were predictors of ICH. In
a multivariate regression model predicting ICH, pre-admission antithrombotic therapy and low platelet count
demonstrated independent risk association. When comparing the temporal trajectories for coagulation variables in the
days leading up to the detection of an ICH, plasma antithrombin significantly increased per patient over time (p = 0.014).
No other temporal trajectories were found.
Conclusions: ICH in adult ECMO patients is associated with a high mortality rate and independently associated with
pre-admission antithrombotic therapy and low platelet count, thus highlighting important areas of potential treatment
strategies to prevent ICH development.
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Background
Extracorporeal membrane oxygenation (ECMO) for re-
spiratory and circulatory support—frequently used in
pediatric intensive care [1]—is increasingly being
employed in adults [2–4]. In addition to the critical condi-
tion of the patients treated, there is significant morbidity
associated with the ECMO treatment itself [5]. A frequent
complication is bleeding, a result of the systemic effects of
cardiopulmonary bypass, causing platelet dysfunction,
platelet consumption, and hemodilution of clotting fac-
tors, in combination with the anticoagulation and an-
tiplatelet therapy administered to reduce the risk of
circuit clotting [6]. In all probabilities, intracranial
hemorrhage is the most devastating bleeding complica-
tion that can occur (ICH) [7] and has previously been
associated with increased mortality in adults receiving
ECMO treatment [8–10]. Despite this, the predictors of
ICH in adult patients treated with ECMO are poorly
understood.
So far, studies investigating the predictors of ICH in
ECMO patients have focused on the pediatric population
[11, 12] with only three studies looking into possible
predictors in adults. In these studies, female sex,
thrombocytopenia, use of heparin, dialysis, creatinine
>2,6 mg/dl (230 μmol/L), duration of ECMO treatment,
increased activated clotting time (ACT), spontaneous ex-
tracranial hemorrhage, renal failure upon intensive care
unit (ICU) admission as well as rapid PaO2 increase and
PaCO2 decrease upon ECMO initiation have been iden-
tified as predictors of ICH [13–15]. Generally, these
studies have been constrained by the limited number of
patients included, making statistical modeling difficult.
In addition, only one of them included patients treated
with both venoarterial (VA) and venovenous (VV)
ECMO.
In this largest retrospective observational cohort study
to date, we explored possible predictors of ICH in ECMO-
treated adult patients.
Methods
Patients
All adult patients (≥18 years) treated with VA or VV
ECMO at the Karolinska University Hospital, Stockholm,
Sweden, between September 2005 and June 2016 were eli-
gible for inclusion. Patients with intracranial hemorrhage
upon admission were excluded. To reduce the influence
of precipitating events, patients were required to have
been on ECMO support for at least 12 h prior to decannu-
lation or the development of an ICH. Medical records, in-
cluding clinical notes, laboratory analysis, monitoring
reports, and brain imaging data were collected from pa-
tient charts. The outcome variable was the presence of an
ICH on a computed tomography (CT) scan.
Variables
Pre-cannulation data
Medical history and clinical charts were retrospectively
reviewed, and the following pre-cannulation data were
collected: age, sex, comorbidities (including a calculation
of the Charlson comorbidity index [16]), Sepsis-related
Organ Failure Assessment (sometimes referred to as Se-
quential Organ Failure Assessment) (SOFA) scores [17],
and an arterial blood gas analysis within 2 h before cannu-
lation. Ongoing antithrombotic therapy prior to admission
(defined in our study as both antiplatelet and anticoagula-
tion therapy), as well as cardiopulmonary resuscitation at
any point during hospitalization were also noted.
ECMO data
ECMO data included the indication for ECMO treat-
ment, the ECMO mode employed (VA or VV ECMO),
and whether conversion (shifting from one mode to the
other) was necessary. Common complications that oc-
curred during the ECMO treatment were also registered,
including septic shock, dialysis, spontaneous extracranial
hemorrhage, and administered blood products post-
cannulation (plasma, platelets, and erythrocyte concen-
trate). We also noted the lowest recorded value during
the ECMO treatment for platelet count, fibrinogen con-
centration, PvCO2 and axillary body temperature, as well
as the highest recorded value for antithrombin concen-
tration, international normalized ratio (INR), venous lac-
tate concentration, venous pH, PvO2, and mean arterial
blood pressure (MAP). By registering the highest/lowest
values, as opposed to medians or means, we were able
to catch temporary critical levels that could precipitate
ICH development, for example, unexpected increases in
MAP or acute decreases in platelet count. For patients
that developed an ICH, variables were only recorded
until the detection of the ICH, which in turn was deter-
mined according to the time the CT scan was per-
formed. Registered follow-up data were 1-month and 6-
month mortality. In addition, for patients with ICH, we
registered hemorrhage location, hemorrhage volume
(calculated by multiplying the hemorrhage length ×
width × height and dividing by two), and Fisher scale
[18]. We also registered the daily mean platelet count,
antithrombin concentration, fibrinogen concentration,
INR and activated partial thromboplastin time (APTT)
on the day the ICH was diagnosed as well as in the
4 days preceding diagnosis—an arbitrary time frame we
believe would incorporate any clinically important
information.
Patient management during ECMO
Patients with potentially reversible acute respiratory and/or
cardiac failure were considered for ECMO treatment. In
acute respiratory failure, a ratio of arterial oxygen partial
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pressure to fraction of inspired oxygen (PaO2/FiO2 ratio)
<80 mmHg (FiO2 1.0) was required. Other criteria in-
cluded peak inspiratory pressure >35 cmH2O (pressure
control), prolonged refractory hypercarbia with acidosis
(pH < 7.10), and Murray score >3 [19]. In acute cardiac fail-
ure, the following criteria increased the chance of accept-
ance for ECMO treatment: central venous oxygen
saturation (ScvO2) <55%, cardiac index <2 L/min m
2 [20],
acidaemia, lactatemia, or vasoactive-inotropic score >45–
50 μg/kg min−1 [21].
Anticoagulation was achieved by a continuous intraven-
ous infusion of unfractionated heparin (UFH) targeting an
APTT of 60–80 s, which was assessed three times daily.
Hourly monitoring using arterial and/or venous blood gas
analysis was performed (Radiometer, Copenhagen,
Denmark), including a separate assessment for activated
clotting time (ACT) (Hemochron Mini II, Helena Labora-
tories, Beaumont, TX, USA, or Hemochron Junior, Scan-
dinavian Medical Partner, Gothenburg, Sweden) with a
treatment target of 180–220 s. After arrival at our ICU, a
tracheostomy was performed within 2 to 3 days, after
which the patients’ sedation was reduced with the goal of
keeping the patient awake with analgosedation. The bed-
side nurse and the physician in charge of the patient con-
tinuously monitored the central nervous system through
serial neurological examinations. This included calculation
of the Glasgow Coma Scale [22], response to verbal direc-
tives or pain, brainstem reflexes, eye opening, and pupil
examination. When an unexpected neurological event oc-
curred (e.g., seizures, mydriasis, anisocoria, delirium, con-
fusion, motor function deficits, or failure to wake up
following withdrawal of sedation), a cerebral CT scan was
performed. Additional cerebral CT scans were also per-
formed whenever the patient was referred for a thoracic
or abdominal CT scan, even without any apparent clinical
indication. A description of the ECMO pumps, oxygena-
tors, ventilators, cannulas and patients monitoring sys-
tems used is included in Additional file 1.
Statistical analysis
For descriptive purposes, continuous data are presented as
medians (interquartile range) and categorical data as num-
bers (proportion). Mann-Whitney U test and chi-square
test were used to compare continuous and categorical vari-
ables, respectively. A univariate regression analysis was
then used to correlate factors indicating a significant trend
(p < 0.1) between ICH and non-ICH cohorts (“lrm” func-
tion in R, “rms”-package) [23]. In the univariate model, un-
imputed data were used. Nagelkerke’s pseudo-R2 was used
to illustrate the pseudo explained variance, where “0” does
not explain and “1” fully explains the model. A multivariate
model, bias-adjusted for multiple parameters, was per-
formed to determine independent risk factors for ICH. In
order to detect significant temporal trajectories in the
coagulation variables of patients that developed an ICH, a
paired t test was used. Moreover, a student’s t test was used
to detect any statistically significant change in the coagula-
tion variables between the day of ICH diagnosis vs. 4 days
prior. The statistical significance level was set to p < 0.05.
The statistical program R was used, utilizing the interface
R-studio Version 1.0.136 [23].
Results
During the study period, 311 adults were admitted for
ECMO treatment. Of these, 24 were excluded from our
study due to <12 h of ECMO treatment, four were ex-
cluded due to the presence of an ICH upon admission
and 30 were excluded because their ECMO treatment
was partially conducted at a different hospital. Two hun-
dred and fifty-three patients were included in the study,
161 of whom were treated with VV ECMO and 92
treated with VA ECMO, while 42 required conversion at
least once. Pulmonary indications were by far the most
common reason for ECMO treatment (n = 224, 89%).
The majority of patients (98.4%) received intravenous
heparin infusion to prevent clotting. The patients that
did not receive heparin infusion did so because they had
ongoing bleeding complications.
ICH events and patient outcome
Fifty-four patients (21%) developed an ICH during their
ECMO treatment. Forty-one of these were intracerebral
hemorrhages (76%), 12 were subarachnoid hemorrhages
(22%), and one was a subdural hemorrhage (2%). The
median hematoma volume for the intracerebral hemor-
rhages was 22.8 mL, and the median Fisher scale for the
subarachnoid hemorrhages was grade 2 (Table 1). The
median time to ICH development from ECMO initiation
was 7 days (4.0–14.5) (Table 4). Compared to non-ICH
cohorts, ICH development was strongly associated with
increased 1-month mortality (81 vs. 28%, p < 0.001,
pseudo-R2 = 0.258) and 6-month mortality (85 vs. 33%,
p < 0.001, pseudo-R2 = 0.248). There was no significant
difference in ICH occurrence between VV and VA
ECMO patients (19 and 27%, respectively, p = 0.283).
Table 1 ICH characteristics
Variables ICH cohort (n = 54)
Intracerebral hemorrhage 41 (76%)
Hematoma volume (mL)a 22.8 (6.24–56.7)
Subdural hemorrhage 1 (2%)
Hematoma volume (mL)a 25.0 (range N/A)
Subarachnoid hemorrhage 12 (22%)
Fisher grade 2 (2–4)
Values are expressed as median (interquartile range) or numbers (proportion)
Abbreviation: ICH intracranial hemorrhage
aCalculated by multiplying the length × width × height of the hemorrhage
and dividing by two
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Predictors of ICH
When comparing ICH with non-ICH cohorts, increased
risk of ICH was associated with the following: pre-
admission antithrombotic therapy (p = 0.018), high pre-
cannulation SOFA coagulation score (p = 0.015) (Table 2),
low platelet count (p < 0.001) (Table 3), spontaneous ex-
tracranial hemorrhage (p = 0.045), amount of adminis-
tered platelets (p = 0.004), and amount of administered
erythrocyte concentrate (p = 0.014) (Table 4).
Independent predictors of ICH
In the regression analysis, we included variables with p
< 0.1. The pre-cannulation SOFA coagulation score was
not included because the data was missing in 50% of pa-
tients (the parameter was not registered at our center
prior to 2012), which would require a high degree of
imputation and weaken any conclusions. The SOFA co-
agulation score is determined by the platelet count,
where a lower platelet count yields a higher score [17].
As expected, a strong co-variance between the pre-
cannulation SOFA coagulation score and low platelet
count (pseudo-R2 = 0.156, data not shown) was also
found, further supporting the removal of this variable
from the regression analysis. Furthermore, due to a
high degree of treatment intensity bias, we also disre-
garded the variables concerning administered blood
products in the regression analysis. The univariate re-
gression analysis confirmed pre-admission antithrom-
botic therapy (p = 0.014), low platelet count (p < 0.001),
and spontaneous extracranial hemorrhage (p = 0.031) as
predictors of ICH. It also recognized septic shock (p =
0.043) and dialysis (p = 0.020) as predictors. In the
multivariate analysis, pre-admission antithrombotic
therapy (p = 0.011, R2 = 0.037) and low platelet count
(p = 0.035, R2 = 0.074) demonstrated independent risk
association (Table 5).
Table 2 ICH vs. non-ICH cohorts: demographics, pre-admission morbidity, pre-cannulation SOFA score, ECMO mode, and indication
Variable ICH cohort (n = 54) Non-ICH cohort (n = 199) p value
Demographics
Age (years) 51.5 (40–61) 50 (32–60) 0.158
Male sex 35 (65%) 127 (64%) 1.000
Pre-admission morbidity
Hypertension 9 (17%) 36 (18%) 0.967
Insulin-dependent diabetes mellitus 5 (9%) 22 (11%) 0.896
Chronic renal disease 2 (4%) 1 (1%) 0.116
Antithrombotic therapy 7 (13%) 7 (4%) 0.018
Charlson comorbidity index 0 (0–1) 0 (0–1) 0.373
Pre-cannulation SOFA score
Total 14 (10.8–16) (26 missing, 48%) 13 (10–15) (106 missing, 53%) 0.443
Respiration 4 (4–4) (25 missing, 46%) 4 (4–4) (95 missing, 48%) 0.340
Coagulation 2 (0–3) (26 missing, 48%) 1 (0–2) (100 missing, 50%) 0.015
Liver 1 (0–2) (26 missing, 48%) 1 (0–2) (102 missing, 51%) 0.960
Cardiovascular 4 (3–4) (25 missing, 46%) 4 (3–4) (95 missing, 48%) 0.742
Neurological 1 (0–2) (25 missing, 46%) 1 (0–2) (98 missing, 49%) 0.726
Renal 1.5 (1–4) (26 missing, 48%) 1 (0–4) (101 missing, 51%) 0.606
ECMO Indication
Pulmonary 48 (89%) 176 (88%)
Cardiac 2 (4%) 17 (9%)
ECPR 4 (7%) 6 (3%)
ECMO mode
Venovenous 31 (57%) 130 (65%) 0.361
Venoarterial 23 (43%) 69 (35%) 0.361
Values are expressed as median (interquartile range) or numbers (proportion)
Italicized text in the p value column indicates a statistically significant correlation (p < 0.05)
Pulmonary indications included pneumonia (n = 102), sepsis (n = 78), respiratory failure (n = 18), ARDS (n = 17), trauma (n = 6), and drowning (n = 3). Cardiac
indications included cardiogenic shock (n = 18) and pulmonary embolism (n = 1)
Abbreviations: SOFA Sepsis-related Organ Failure Assessment (also known as Severity Organ Failure Assessment), ECMO extracorporeal membrane oxygenation, ICH
intracranial hemorrhage, ECPR extracorporeal cardiopulmonary resuscitation
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Table 3 ICH vs. non-ICH cohorts: laboratory variables
Variable ICH cohort (n = 54) Non-ICH cohort (n = 199) p value
Lab biochemistry
Platelet counta (×109/mL) 31 (17–46) 48 (27–84) <0.001
INRb 1.5 (1.2–1.8) 1.4 (1.2–1.6) 0.147
Antithrombinb (kIU/L) 0.90 (0.78–1.06) 0.93 (0.82–1.09) 0.542
Fibrinogena (g/L) 2.8 (1.5–4.3) 2.7 (1.6–3.8) 0.814
v-Lactateb (mmol/L) 4.7 (3.0–9.7) (4 missing, 7%) 3.7 (2.7–7.7) (22 missing, 11%) 0.174
Blood gas analysis
Arterialc
a-pH 7.26 (7.18–7.33) (16 missing, 30%) 7.25 (7.16–7.34) (51 missing, 26%) 0.703
PaCO2 (kPa) 6.90 (6.10–7.65) (17 missing, 31%) 7.27 (6.00–9.90) (50 missing, 25%) 0.481
PaO2 (kPa) 7.39 (6.36–8.81) (16 missing, 30%) 7.34 (6.17–9.00) (50 missing, 25%) 0.661
Venous
v-pHa 7.22 (7.17–7.26) (4 missing, 7%) 7.23 (7.17–7.28) (22 missing, 11%) 0.184
PvCO2 (kPa)
b 7.80 (7.38–8.95) (4 missing, 7%) 8.04 (7.25–9.00) (22 missing, 11%) 0.890
PvO2 (kPa)
a 4.30 (3.73–4.80) (4 missing, 7%) 4.46 (4.00–5.00) (22 missing, 11%) 0.105
Values are expressed as median (interquartile range) or numbers (proportion)
Italicized text in the p value column indicates a statistically significant correlation (p < 0.05)
Abbreviations: ICH intracranial hemorrhage, INR international normalized ratio
aLowest value during ECMO support and before ICH diagnosis (if applicable)
bHighest value during ECMO support and before ICH diagnosis (if applicable)
cRegistered within 2 h before cannulation
Table 4 ICH vs. non-ICH cohorts: clinical variables
Variable ICH cohort (n = 54) Non-ICH cohort (n = 199) p value
Administered blood productsa
Plasma (mL) 2804 (1434–5674) (3 missing, 6%) 1873 (690–4887) (22 missing, 11%) 0.061
Platelets (mL) 1239 (275–3265) (3 missing, 6%) 370 (0–2072) (22 missing, 11%) 0.004
Erythrocyte concentrate (mL) 3576 (2155–6848) (3 missing, 6%) 2471 (1027–6531) (22 missing, 11%) 0.014
Mean arterial pressureb (mmHg) 99 (89–113) (1 missing, 2%) 100 (92–109) (16 missing, 8%) 0.791
Axillary temperature <36 °Ca 12 (23%) (1 missing, 2%) 53 (29%) (16 missing, 8%) 0.463
Spontaneous extracranial hemorrhagea 32 (59%) 85 (43%) 0.045
CPRc 11 (20%) 34 (17%) 0.719
Septic shocka 24 (44%) 59 (30%) 0.059
Dialysisa 52 (96%) 171 (86%) 0.063
Converted 12 (22%) 30 (15%) 0.296
ECMO days at ICH diagnosis 7 (4.0–14.5) – –
Days on ECMO 12 (5–19) 7 (4.0–15) 0.057
1-month mortality 44 (81%) 52 (28%) (13 missing, 7%) <0.001
6-month mortality 46 (85%) 61 (33%) (13 missing, 7%) <0.001
Values are expressed as median (interquartile range) or numbers (proportion)
Italicized text in the p value column indicates a statistically significant correlation (p < 0.05)
Abbreviations: ICH intracranial hemorrhage, CPR cardiopulmonary resuscitation, ECMO extracorporeal membrane oxygenation
aDuring ECMO support and before ICH diagnosis (if applicable)
bHighest value during ECMO support and before ICH diagnosis (if applicable)
cDuring hospitalization and before ICH diagnosis (if applicable)
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Coagulation trajectories prior to ICH
APTT, platelet count, INR, antithrombin, and fibrinogen
concentration during the 4 days preceding the diagnosis of
an ICH as well as on the day of ICH diagnosis were
assessed. Figure 1 displays the daily means for each patient,
and Table 6 demonstrates the combined mean values on
the day of ICH diagnosis and 4 days prior to this. The re-
sults show that, on both an individual and group level, the
APTT consistently stayed within the therapeutic range and
there was no significant change in APTT preceding ICH
diagnosis (t test p = 0.289, paired t test p = 0.254, Fig. 1,
Table 6). In the paired t test, the only parameter that sig-
nificantly changed per patient over time preceding ICH
diagnosis was antithrombin (increasing levels) (p = 0.014).
Apart from this, no other significant temporal trajectories
Table 5 ICH risk factors: uni- and multivariate analysis
Variable Univariate
p value
Nagelkerke’s
pseudo R2
Multivariate
p value
Pre-admission antithrombotic
therapy
0.014 0.036 0.011
Platelet count <0.001 0.074 0.035
Septic shock 0.043 0.025 0.280
Dialysis 0.020 0.033 0.215
Spontaneous extracranial
hemorrhage
0.031 0.028 0.221
Italicized text in the p value column indicates a statistically significant
correlation (p < 0.05)
Abbreviations: ICH intracranial hemorrhage, ECMO extracorporeal
membrane oxygenation
Fig. 1 ICH cohort: temporal trajectories for coagulation variables prior to ICH diagnosis. Calculated using the daily means in the 4 days preceding
the diagnosis of an ICH as well as on the day of ICH diagnosis. The horizontal axis indicates the amount of days prior to detection of an ICH,
where “0” is the same day that the ICH was later detected. The horizontal blue lines represent the combined daily mean values for all patients,
and the gray area represents the corresponding 95% confidence interval. APTT activated partial thromboplastin time, INR international normalized ratio
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were found and no significant difference on group level
could be detected.
Discussion
In this observational cohort study, we sought to identify
predictors of ICH in adult patients receiving ECMO treat-
ment. Out of 253 patients, 54 (21%) developed an ICH. In
patients that developed an ICH, the mortality was 81% at
1 month and 85% at 6 months, compared to 28 and 33%,
respectively, in patients without an ICH. We identified (i)
pre-admission antithrombotic therapy, (ii) high pre-
cannulation SOFA coagulation score, (iii) low platelet
count, (iv) septic shock, (v) dialysis, (vi) spontaneous ex-
tracranial hemorrhage, (vii) administered platelets, and
(viii) administered erythrocyte concentrate as predictors
of ICH development. Of these, pre-admission antithrom-
botic therapy and low platelet count were independent
risk factors. Notably, this is the first time that pre-
admission antithrombotic therapy, high pre-cannulation
SOFA coagulation score, and septic shock have been iden-
tified as predictors of ICH. In addition, when comparing
the temporal trajectories for coagulation variables in the
days leading up to the detection of an ICH, there was a
significant per patient increase in antithrombin concentra-
tion over time, while the means remained largely un-
changed. To the best of our knowledge, this is the largest
study of ICH predictors in adult patients on ECMO and
contributes new findings that are important for patient
management and future study design.
We included both VA and VV ECMO patients in our
study, contrary to one of the previous studies that ex-
cluded VA patients on the basis of an increased risk of
systemic thromboembolism from thrombus formation
within the ECMO unit [15]. However, this complication
is infrequent [24] due to the heparin infusion regimen as
well as the bedside staffs’ continuous attentive observa-
tion of the ECMO circuit for signs of clotting. Moreover,
to the best of our knowledge, a comparison between VA
and VV ECMO of the frequency of systemic thrombo-
embolism has not been studied in the adult population
and is thus only theoretical, further supporting the inclu-
sion of both patient categories in the analysis.
Twenty-one percent of our patients experienced an ICH
during ECMO treatment. This is in the upper range of the
7–19% previously reported in similar studies [13–15].
However, in a number of cases, the ICHs we identified
were diagnosed using CT scans performed in the absence
of neurological symptoms (i.e., a cerebral CT scan that
was performed at the same time as a CT scan of the
thorax or abdomen). A previous study, conducted at our
center, on adult and pediatric ECMO patients treated be-
tween 1994 and 2004 found that 24% of those with an
intracranial pathology (defined as ICH, cerebral infarction,
or general edema) presented with no clinical neurological
signs before performing the diagnostic CT, further sug-
gesting that low utilization of neuroimaging contributed
to underreporting of ICH [25]. It is possible, therefore,
that our CT examination policy was a contributing factor
to the high diagnostic rate of ICH in our cohort. However,
in previous studies, the routine for performing cerebral
CT scans in the absence of neurological symptoms is
poorly described, making comparison difficult. With re-
spect to outcome, we found that the 1-month mortality
rate for patients who experienced an ICH was 81%, com-
pared to 28% in non-ICH patients, which is in accordance
with current literature [8, 13–15]. Consequently, ICH was
associated with a considerable risk for mortality in this
ECMO population, with a somewhat higher incidence of
ICH occurrence compared to previous studies.
Pulmonary indications were the most common reasons
for ECMO treatment in this cohort (n = 224, 89%). Pre-
viously, other groups have tried to establish if the indica-
tion for ECMO was associated with a higher risk of ICH
[13, 14] but were limited by few data points in several of
the subgroups, making statistical analysis unreliable.
Moreover, while we determined indications for ECMO
treatment by denoting the most severely affected organ
system, patients usually presented with failure of mul-
tiple organ systems, further confounding this param-
eter. Thus, we chose not to include this variable in
further analysis.
Prior to our study, pre-admission antithrombotic therapy
as a predictor of ICH had not been assessed in ECMO-
treated adults [7, 13–15]. We identified the parameter as
an independent predictor of ICH, with 50% of patients
Table 6 ICH cohort: coagulation variables on the day of ICH diagnosis and 4 days prior
Variable 4 days prior to ICH diagnosis Day of ICH diagnosis t test p value Paired t test p value
APTT (s) 69 (57–89) 78 (60–95) 0.289 0.254
Platelet count (×109/mL) 76 (52–99) 54 (35–77) 0.156 0.263
Antithrombin (kIU/L) 0.70 (0.56–0.76) 0.71 (0.63–0.80) 0.374 0.014
Fibrinogen (g/L) 4.50 (2.80–6.13) 4.40 (2.70–6.00) 0.467 0.496
INR 1.13 (1.05–1.40) 1.20 (1.10–1.30) 0.816 0.054
Values are expressed as medians (interquartile range)
Italicized text in the p value column indicates a statistically significant correlation (p < 0.05)
Abbreviations: APTT activated partial thromboplastin time, INR international normalized ratio
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with pre-admission antithrombotic therapy who were ad-
mitted for ECMO treatment developing an ICH. In theory,
long-term antithrombotic therapy could have rendered
these patients hemostatically difficult to control using the
heparin infusion regimen. Alternatively, there could be a
prolonged drug effect at play that is difficult to take into
account. However, we have not found any studies to guide
us in this area. A limitation to the variable was that we did
not differentiate between different forms of antithrombo-
tics. This could be important as they have different mecha-
nisms of action, although differentiating and subgrouping
the antithrombotics would yield extremely small subgroups
and make statistical modeling difficult. For descriptive
purposes, a compilation of the different forms of pre-
admission antithrombotic therapy is included in Additional
file 2: Table S1. Our results imply that patients with pre-
admission antithrombotic therapy were at increased risk of
developing an ICH during ECMO treatment, but its spe-
cific role in different subgroups needs to be further
evaluated.
We further identified low platelet count, amount of
administered platelets, and high pre-cannulation SOFA
coagulation score as predictors of ICH. Low platelet
count, determined by the lowest platelet count recorded
during the ECMO treatment, was identified as an inde-
pendent predictor. Previously, Kasirajan et al. reported
that thrombocytopenia was an independent predictor of
ICH [13] but the results have not been confirmed by
others, possibly due to a high platelet count and/or due
to the low incidence of ICH in the patient cohorts in
similar studies [14, 15]. The impact of high pre-
cannulation SOFA coagulation score has been assessed
once before, albeit not as a continuous variable, when
Luyt et al. distinguished patients with a SOFA coagula-
tion score >2, compared to those with a score ≤2, at
ECMO initiation. However, in their cohort of 12 patients
with an ICH, only one met these criteria [15]. The total
amount of administered platelets was another predictor
of ICH in our study and has been identified as such pre-
viously [14]. However, since patients are administered
platelet transfusions to combat their low platelet count,
thus introducing a potent treatment bias, this parameter
can just as easily be interpreted as an identification of
patients with thrombocytopenia rather than acting a risk
factor on its own. Although this remains unknown, no
prospective study has been designed to address the issue.
Clinically, if there were no signs of bleeding, we used
platelet counts <25–30 × 109/mL as the arbitrary thresh-
old for platelet transfusion. Lastly, in the temporal tra-
jectories of patients with ICH, there was no significant
change in platelet levels in the days leading up to the de-
tection of an ICH. This can be attributed to the fact that
not all bleedings were detected following the develop-
ment of a neurological symptom(s), which makes it
more difficult to determine the exact time of ictus. In
addition, the values were achieved by calculating the
daily average of each patients’ platelet count, which
meant that momentary decreases, which could have led
to hemorrhaging, did not show if the rest of the platelet
counts that day were normal. Hence, low platelet count,
both pre-cannulation and during ECMO treatment, was
a predictor of ICH.
Spontaneous extracranial hemorrhage as a significant
predictor of ICH in adult patients treated with ECMO
has only been assessed once previously, with significant
results [14]. This can be attributed to the loss of platelets
and coagulation factors that occur following major
bleeding, or to the fact that patients who are hemostati-
cally unstable are more likely to bleed. The most com-
mon bleeding sites in our study were pulmonary,
cannula insertion sites, gastrointestinal tract, abdominal
cavity, and thoracic cavity. The amount of administered
erythrocyte concentrate was also identified as a predictor
of ICH. However, since patients are administered
erythrocyte concentrate transfusions following major
bleeding, this parameter is probably an identification of
the patients with extracranial hemorrhage rather than a
risk factor on its own, even if this remains unknown as
no prospective study addressing this exists. Hence, spon-
taneous extracranial hemorrhage is associated with an
increased risk for ICH but the precise mechanism be-
hind it needs to be further assessed.
The risk of ICH was higher in patients who required
dialysis, which is in accordance with previous studies;
Kasirajan et al. showed that dialysis and hypercreatinine-
mia predicted ICH development [13], and Luyt et al.
showed a correlation between renal failure at ICU ad-
mission and increased risk of ICH [15]. However, the
precise mechanism of action needs to be further
assessed. Evidence is also warranted to determine if the
increased risk of ICH is a result of the dialysis treatment
or the conditions that require dialysis. Overhydration
was the main indication for dialysis at our ECMO center,
with acute kidney injury as the second most common in-
dication, and the number of patients who received dialy-
sis was high in both ICH and non-ICH cohorts (96 and
86%, respectively).
Finally, antithrombin significantly increased over time
in patients who developed an ICH, with INR increase
showing a trend towards significance. However, as
shown in Fig. 1b, most ICH patients had antithrombin
values within the reference range, making it difficult to
draw conclusions based on the temporal trajectories
alone. One could hypothesize that the significant tem-
poral trajectory found was due to a general improvement
of hemostatically unstable patients’ coagulation ability
over time. Alternatively, it could be attributed to the fact
that patients were, in some cases, administered
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antithrombin to combat heparin resistance, facilitate hep-
arin effect, or reduce fibrin deposition in the ECMO cir-
cuit. However, the exact role of this correlation remains to
be determined. Moreover, there was no significant change
in APTT (Table 6), indicating that this per patient trajec-
tory probably played a minor role in the development of
ICH. The results also showed that the average patient had
an APTT within the therapeutic range (Fig. 1a, Table 6).
In the clinical setting, APTT is used to guide the heparin
infusion regimen. This therefore suggests that the bleed-
ings were not caused by heparin treatment errors (i.e.,
overdose). However, there are some solitary outliers in
Fig. 1a, which could be the result of incorrect heparin ad-
ministration or repetitive contamination when conducting
the laboratory measurements of APTT. APTT was not in-
cluded in the paired testing between ICH and non-ICH
cohorts due to the risk of bias, as APPT is controlled by
the amount of administered heparin and, accordingly, a
non-therapeutic APTT also results in the physician adjust-
ing the heparin infusion. To conclude, antithrombin sig-
nificantly increased over time in patients who developed
an ICH, but the clinical significance behind this is debat-
able. In addition, due to the lack of significant change in
APTT in the days leading up to ICH diagnosis, coupled
with the fact that the average patients’ APTT was within
the therapeutic range, we concluded that the ICHs were
not the result of incorrect heparin administration.
Clinical implications and future research
Although this is a retrospective study, with its inherent
limitations, our research highlights the importance of
closely monitoring predictors of ICH. While we acknow-
ledge that ECMO is a last resort treatment that is con-
sidered only after great scrutiny, it is important to
identify the ICH predictors that can be targeted with in-
terventions or where earlier weaning from ECMO could
be attempted. Low platelet count can be combated by
decreasing the threshold for platelet transfusion; this
must however be balanced against the risk for throm-
bosis. Also, considering the fact that a number of pa-
tients developed ICH despite a normal mean platelet
count, as is highlighted in Fig. 1e, one should consider
the value of performing “thrombocyte function tests”
(i.e., multiplate) on this patient group on a regular basis,
as platelet dysfunction can lead to the development of
ICH even in the absence of thrombocytopenia [26]. Pre-
admission antithrombotic therapy, high pre-cannulation
SOFA coagulation score, septic shock, dialysis, and spon-
taneous extracranial hemorrhage may help to identify the
patients prone to ICH where more rigorous neurological
checks and earlier weaning from ECMO could be
attempted. Considering the high mortality associated with
an ICH in patients on ECMO, prospective studies evaluat-
ing risk factors for ICH in this patient group are
warranted, as well as studies on management and predic-
tors of outcome after the occurrence of an ICH.
Conclusions
ICH is a frequent complication in adult patients treated
with ECMO and associated with increased mortality. We
identified pre-admission antithrombotic therapy, low plate-
let count, high pre-cannulation SOFA coagulation score,
spontaneous extracranial hemorrhage, dialysis, and septic
shock as predictors of ICH during ECMO treatment, with
pre-admission antithrombotic therapy and low platelet
count identified as independent risk factors. In the clinical
setting, risk factor identification may help initiate steps to
lower the risk of ICH in patients undergoing ECMO treat-
ment. Prospective trials are warranted to identify additional
risk factors and their mechanisms of action.
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